Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion.
Betina BiagettiMarta Araujo-CastroEdelmiro Menéndez TorreIría Novoa-TestaFernando CordidoEider Pascual CorralesVíctor Rodríguez BerrocalFernando Guerrero-PérezAlmudena VicenteJuan Carlos PercovichRogelio García CentenoLaura GonzálezMaría Dolores Ollero GarcíaAna Irigaray EcharriMaría Dolores Moure RodríguezCristina Novo-RodríguezMaría CalatayudRocío Villar-TaiboIgnacio BernabéuCristina Alvarez-EscolaPamela Benítez ValderramaCarmen Tenorio-JiménezPablo Abellán GalianaEva Venegas MorenoInmaculada González MoleroPedro IglesiasConcepción BlancoFernando Vidal-Ostos De LaraPaz de MiguelElena López MezquitaFelicia Alexandra HanzuIban AldecoaSilvia AznarCristina Lamas OliveiraAnna AulinasQueralt Asla RocaPaola GraciaJosé María Recio CórdovaMariola AvilesDiego Asensio-WandoselMiguel SampedroRosa CámaraMiguel PajaIgnacio Ruz-CaracuelCarmen Fajardo-MontañanaEsteban Cordero AsanzaElena Martinez-SaezMónica MarazuelaManel Puig-DomingoPublished in: European journal of endocrinology (2024)
In GH&PRL-PA, the biochemical control achieved with fgSRL as monotherapy is substantially worse than in patients harboring GH-PA, supporting the inclusion of cabergoline as first-line medical treatment in combination with fgSRLs in these subgroups of patients.